Search results
Her lab was part of the 2012 multicenter study organized by Ian Lipkin's group at Columbia University to assess the actual role of XMRV in ME/CFS. Dr. Hanson has a current project to examine the microbiome of ME/CFS patients and controls, in collaboration with Dr. Ruth Ley (Cornell Microbiology) and Susan Levine, M.D. (Manhattan, NY).
4 days ago · After helping fight the severe acute respiratory syndrome outbreak with his Chinese counterparts in 2003, Lipkin is known in China as a front-line trooper who shared his expertise to assess the state of the disease and helped orchestrate a strategy for virus-containment and curtailing infections and fatalities.
5 days ago · At a day-long homage to Ian Lipkin on April 3, for instance, where luminaries of the infectious disease world celebrated the career of the Columbia University virus hunter, Avi Nath joined a panel about ME. At one juncture, Nath praised the ability of Lipkin to inspire trust in “…even the population of ME/CFS as difficult as they might be…”
2 days ago · Impacts. COVID-19 portal. v. t. e. SARS-CoV-2, the causative agent of COVID-19, was first introduced to humans through zoonosis (transmission of a pathogen to a human from an animal), and a zoonotic spillover event is the origin of COVID-19 that is considered most plausible by the scientific community.
4 days ago · TWiV is a weekly netcast about viruses - the kind that make you sick. Professors Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler and science writer Alan Dove and guests deconstruct viruses, how they cause illness, and dissect the latest research.
- (2K)
2 days ago · Montagnier was the co-founder of the World Foundation for AIDS Research and Prevention and co-directed the Program for International Viral Collaboration. He was the founder and a former president of the Houston-based World Foundation for Medical Research and Prevention.
2 days ago · In the United States, nirmatrelvir/ritonavir is indicated for the treatment of mild-to-moderate COVID‑19 in adults who are at high risk for progression to severe COVID‑19, including hospitalization or death.
